REG - GSK PLC - GSK plc 2024 Annual Report on Form 20-F

GSKAnnouncement

03/03/2025 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250303:nRSC1635Za&default-theme=true

RNS Number : 1635Z  GSK PLC  03 March 2025

Issued: 3 March 2025, London UK

 

GSK plc 2024 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, GSK plc ("GSK") announces that on 3 March 2025 it filed with
the Securities and Exchange Commission an Annual Report on Form 20-F that
included audited financial statements for the year ended 31 December 2024.
GSK's 2024 Annual Report on Form 20-F is available online at GSK's website at:
https://annualreport.gsk.com (https://annualreport.gsk.com) and also online at
www.sec.gov (http://www.sec.gov) .

A hard copy version of the GSK 2024 Annual Report, together with the Notice of
Annual General Meeting, will be available on or about 24 March 2025.

Shareholders have the ability to receive, upon request, a hard copy version of
GSK's complete audited financial statements for the year ended 31 December
2024, free of charge, by either:

 

 (i)                    writing to Computershare Investor Services, our registrars in the UK, at the
                        following address: Computershare Investor Services, The Pavilions, Bridgwater
                        Road, Bristol BS13 8AE, United Kingdom, or by telephone on +44 (0) 370 707
                        1595 (please use the country code if calling from outside the UK);

 (ii)                   writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the
                        following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN
                        55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453
                        2128 (outside the US); or

 (iii)                  contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll
                        free).

 

 

About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria Whyte

Company Secretary

3 March 2025

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBRGDXIGGDGUX